Route is rarely the largest line item. Price is set by which product is dispensed, whether it is a generic vial or a branded device, whether a health plan covers it after prior authorization, and who pays for the recurring blood work. A generic intramuscular ester and a branded subcutaneous auto-injector sit far apart on cost while delivering the same hormone.
The product sets the price, not the route
Testosterone cypionate and testosterone enanthate have been sold in the United States as generic injectable solutions for decades. They are inexpensive relative to most specialty medication, and pharmacies dispense them in vials. Their labeling is specific about route. Testosterone cypionate injection is for intramuscular use only, and the generic enanthate solutions carry the same intramuscular route.
The approved subcutaneous option is a different commercial product. Xyosted is a testosterone enanthate auto-injector approved under NDA 209863 and labeled for subcutaneous use. It is a single-use device rather than a vial, and device presentations in this category cost more than the generic solution they contain.
That is the real fork. Someone comparing routes is usually comparing a cheap generic vial against a branded device and attributing the gap to the route rather than to the packaging.
Subcutaneous use of a vial product is off label
Some prescribers direct patients to give cypionate or generic enanthate under the skin, and published clinical work has examined that practice. It remains off-label use, because those labels specify intramuscular administration. Off-label prescribing is legal and routine in US medicine. It matters for cost in one narrow way: a payer reviewing a claim looks at the labeled indication and route, and an off-label administration can complicate an appeal that was already going to be contested.
The clinic-administered product has a third cost structure
Testosterone undecanoate, sold as Aveed, is intramuscular only and carries a boxed warning for serious pulmonary oil microembolism reactions and anaphylaxis. Its labeling requires patients to be observed in the healthcare setting for 30 minutes after each injection, and the product is available only through a restricted program called the Aveed REMS Program.
Longer intervals between injections mean fewer pharmacy fills, but every administration is a clinic encounter with a visit or facility charge attached. For someone on a high-deductible plan, a handful of billed encounters can outweigh a cheaper drug.
What a plan asks for before it pays
Coverage is conditional almost everywhere. The labels for cypionate, enanthate, and the subcutaneous auto-injector all direct prescribers to confirm the diagnosis of hypogonadism by measuring serum testosterone in the morning on at least two separate days and finding those concentrations below the normal range. Payers frequently mirror that language in prior authorization criteria.
The same labels state that safety and efficacy in men with age-related hypogonadism have not been established. A request built around energy, body composition, or general wellness rather than a documented diagnosis is the request most likely to be denied. Medicare Part D plans cover outpatient drugs through their own formularies, with tier placement and utilization management set plan by plan, so two people in the same city can face different out-of-pocket costs for the same vial.
Prior authorization is not unique to testosterone. Health plans apply similar coverage logic across other prescription categories, and comparing how different services explain it is a useful exercise. Providers such as Ro, Hims and Hers, and HealthRX, whose GLP-1 insurance coverage guide lays out the criteria a plan checks before approving a weight-management drug, show how much the rules vary by product class rather than by route.
Cash pricing and what a monthly figure covers
Cash-pay men’s health services quote a monthly number, and the number does not always describe the same bundle. Programs including Hone Health, Marek Health, Defy Medical, and FormBlends differ in whether the quoted figure includes the medication itself, the initial consultation, follow-up visits, and the repeat blood panels, and resolving that is more useful than comparing two headline prices. Where a compounded preparation is involved, it is not an FDA-approved product, which is a separate matter from what it costs.
One thing no legitimate program changes is the prescription requirement. Testosterone is a Schedule III controlled substance under the Controlled Substances Act, a status stated plainly on the cypionate, enanthate, and auto-injector labels. Sourcing it without a prescription is illegal and removes every safeguard that makes the therapy monitorable.
| Cost element | Generic intramuscular vial | Subcutaneous auto-injector | Clinic-given undecanoate |
|---|---|---|---|
| Drug acquisition | Lowest, long-standing generic | Higher, branded device | Higher, branded |
| Route on the label | Intramuscular only | Subcutaneous | Intramuscular only |
| Where it is given | Per prescriber arrangement | Per prescriber arrangement | Healthcare setting only |
| Added encounter cost | Routine follow-up | Routine follow-up | Observation period each time |
| Restricted program | No | No | Aveed REMS Program |
| Lab monitoring cost | Same either way | Same either way | Same either way |
Monitoring is the recurring cost people forget
Testosterone therapy is not a one-time purchase. Labeling for the subcutaneous auto-injector directs clinicians to monitor hematocrit approximately every 3 months to detect increased red cell mass and polycythemia. Guidelines from the Endocrine Society and from the Society for Endocrinology describe continuing assessment of symptoms, testosterone concentrations, hematocrit, and prostate health at intervals the prescriber sets.
Whoever pays for those panels belongs in the price comparison. A cheap prescription attached to uncovered quarterly lab work is not a cheap program, and a slightly costlier program that includes the panels can end up lower.
Frequently asked questions
Does insurance treat the two routes differently?
Usually the plan is looking at the product code rather than the route. The generic vials tend to sit on a low formulary tier, while the branded auto-injector often needs prior authorization or a step through a generic first. The clinical criteria for approval are generally the same either way.
Why is the auto-injector more expensive than a vial of the same drug?
Because the price reflects the delivery device and its approval, not just the hormone. Xyosted is a branded single-use presentation approved under its own application. Generic enanthate solution has competing manufacturers and decades of price erosion behind it, which the device product does not.
Are lab costs included in a telehealth membership?
Sometimes. Some programs bundle the panels into the monthly fee, others bill them separately or send the order to an outside lab that invoices independently. Asking which panels are included, how often they are drawn, and who is billed avoids the most common surprise in these programs.
Can the route be chosen to lower cost?
Route is a clinical decision that depends on the product, the diagnosis, and the individual, and it belongs to the prescriber. Cost can reasonably be raised as one factor in that conversation, but choosing a route to hit a price and then working backward inverts the order the decision should follow.
Is a cheaper source without a prescription ever reasonable?
No. Testosterone is federally scheduled, and product bought outside the regulated supply chain has no verified identity, strength, or sterility. The FDA maintains resources on counterfeit medicine and on evaluating online pharmacies for exactly this situation.
